Biotechnology company 4basebio PLC (AIM: 4BB) announced on Wednesday that it has obtained Good Manufacturing Practice (GMP) certification from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its DNA manufacturing facility in Cambridge.

The certification authorises the company to manufacture and supply Investigational Medicinal Products (IMP) Drug Substance and Critical Starting Biological Medicinal materials for Advanced Therapy Medicinal Products (ATMPs).

This milestone strengthens 4basebio's position in advanced therapeutics and moves the company closer to commercialisation, supporting future clinical applications and patient care in the ATMP sector.

4basebio is focused on developing high-performance synthetic DNA products and non-viral, cell-targeting delivery systems for research, therapeutic and pharmacological applications. Its goal is to lead the market in providing high-quality DNA products and advanced delivery solutions.